Looks like Roche is losing its market advantage with its drug like Herceptin, Rituxan and Avastin. Their pricing is being undercut by biosimilar as its drugs patent protection runs out. Now, they are facing fall in market share and reduced profit margin to competition. If they want to maintain its advantage, Roche will have to look to something better and with long patent protection.
Oh, look what have we got here? A UNIQUE Goose with more than 10 years patent protection on the window. And I will tell you this. Based on its past action, Roche is no Scrooge.
